Log in
Products
Latest News
FAQ
Log in
|
Search
Search
Filters
Clear All
Study Phase
Early Phase 1
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase 4
Not Applicable
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Completed
Suspended
Terminated
Withdrawn
Study Type
Interventional
Observational
Expanded Access
Others
Eligibility Sex
All
Female
Male
Healthy Volunteers
All
Include
Exclude
Found
1
clinical trials
|
View Analysis
Sort by:
Newest First
A Phase II Trial of Cabozantinib with Patients with Refractory GCTs
Phase 2
Recruiting
Conditions
Seminoma
Ovarian Germ Cell Tumor
Germ Cell Tumor
Non-seminomatous Germ Cell Tumor
Interventions
Drug: Cabozantinib
Subscribe
First Posted Date
2021-05-06
Last Posted Date
2025-01-09
Lead Sponsor
Jennifer King
Target Recruit Count
50
Registration Number
NCT04876456
Locations
🇺🇸
Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States
Subscribe
Prev
1
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy